Robert W. Baird Cuts Certara (NASDAQ:CERT) Price Target to $13.00

Certara (NASDAQ:CERT) had its price target reduced by Robert W. Baird from $18.00 to $13.00 in a research report released on Tuesday,Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

Other analysts have also issued research reports about the company. Barclays cut their target price on Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 15th. KeyCorp reduced their target price on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Friday, September 27th. Finally, JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $15.92.

Certara Stock Performance

NASDAQ:CERT opened at $10.99 on Tuesday. Certara has a twelve month low of $9.99 and a twelve month high of $19.87. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. The stock has a market cap of $1.77 billion, a P/E ratio of -21.98, a PEG ratio of 4.88 and a beta of 1.51. The business’s 50-day moving average price is $11.07 and its two-hundred day moving average price is $13.75.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. As a group, equities analysts predict that Certara will post 0.27 EPS for the current fiscal year.

Insider Buying and Selling at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Institutional Trading of Certara

Several large investors have recently added to or reduced their stakes in CERT. Quest Partners LLC purchased a new stake in shares of Certara in the 3rd quarter worth about $367,000. Zions Bancorporation N.A. raised its stake in Certara by 18.5% in the third quarter. Zions Bancorporation N.A. now owns 76,811 shares of the company’s stock worth $899,000 after buying an additional 11,995 shares in the last quarter. KBC Group NV lifted its holdings in Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after buying an additional 1,584 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in Certara by 6.8% in the third quarter. Oppenheimer Asset Management Inc. now owns 211,224 shares of the company’s stock worth $2,473,000 after buying an additional 13,500 shares during the period. Finally, Geneva Capital Management LLC boosted its position in Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock valued at $64,525,000 after acquiring an additional 37,392 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.